Press Releases

Scientists isolate new antibodies to fight human respiratory syncytial virus (RSV) – 13 February 2017
Researchers from VIB, UGent, the Geisel School of Medicine at Dartmouth and several collaborators developed a new antiviral strategy to fight human respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infections in children. The approach hinges on the use of single-domain antibodies, also known as Nanobodies®, which target and neutralize a vital protein in the virus, rendering it unable to enter lung cells. The research, published in the leading scientific journal Nature Communications, elucidates how these Nanobodies® interact with and neutralize the virus and demonstrates their ability to successfully protect mice from RSV infection and related inflammation.
Read more

Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax™-based Respiratory Syncytial Virus Vaccine Candidate – 13 October 2016
Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced positive topline results from its Phase 1 trial evaluating the safety and immunogenicity of DPX-RSV, its DepoVax™-based, small B cell epitope peptide vaccine candidate for respiratory syncytial virus (RSV). The results six months or more after vaccination confirmed earlier-reported interim data on the ability of DepoVax™- formulated antigens to generate a relevant, durable immune response.
Read more

Positive Interim Phase 1 Data for DepoVax™-based Respiratory Syncytial Virus (RSV) Vaccine Candidate – 6 July 2016
Immunovaccine Inc. (“Immunovaccine” or the “company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that a team of investigators has completed an interim analysis of the safety and immunogenicity of its DepoVax™ prophylactic respiratory syncytial virus (RSV) vaccine candidate (DPX-RSV) in a Phase 1 clinical trial in healthy older adult volunteers. The safety analysis indicates that the DPX-RSV was well tolerated among all study participants, with no serious adverse events (SAEs) recorded. Furthermore, immunogenicity data supported DPX-RSV’s ability to generate a relevant immune response; the vaccine candidate obtained antigen-specific antibody responses in 75 percent of subjects vaccinated with the lower dose, and 100 percent of those vaccinated with the higher dose.
Read more

Vaccine candidate for RSV well tolerated in patients in first part of Phase 1 clinical trial – 15 December 2015
​Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, announced its Respiratory Syncytial Virus vaccine candidate (“DPX-RSV”) was well tolerated in the Phase 1 study’s first 20 participants, of which 8 subjects received the DPX-RSV vaccine. The RSV vaccine candidate has been developed by Bert Schepens, Walter Fiers and Xavier Saelens (VIB/UGent).
Read more

Immunovaccine’s vaccine candidate for Respiratory Syncytial Virus is well tolerated in patients in Phase 1 clinical trial – 30 October 2015
​Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that safety data from a Phase 1 clinical study showed that its DepoVax™ prophylactic Respiratory Syncytial Virus vaccine candidate (“DPX-RSV”) was well tolerated in the Phase 1 study’s first 20 patients, of which 8 subjects received the DPX-RSV vaccine. This data marks an important milestone for Immunovaccine as it provides the first safety profile of the DepoVax™-based vaccines for infectious diseases in healthy adults.
Read more

Immunovaccine Initiates Clinical Trial with DPX-RSV Vaccine – 30 June 2015
​Halifax, Nova Scotia; June 30, 2015 – Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX: IMV; OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it has enrolled the first healthy adult volunteer in a Phase 1 clinical study of its respiratory syncytial virus (RSV) vaccine.
Read more